Skip to main content
OpenTrials
Completed

NCT Number: NCT03750565

Multiple Dose Ethnobridging PK Study in Healthy Subjects

A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Theravance Biopharma Investigational Site

Cypress, California, 90630, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For All subjects:

  • Male or female between 18 to 55 years old
  • Female subjects must have documentation of a negative serum pregnancy test,
  • Female subjects must be either of non-childbearing potential or if of childbearing potential use a highly efficient birth control method
  • Male subjects must be vasectomized with documented medical assessment of the surgical success, or use acceptable contraception
  • All male subjects must agree to refrain from sperm donation during the study and for at least 7 days after the last dose of study drug.
  • Body Mass Index (BMI) 18 to 32 kg/m2, inclusive, and weighs at least 50 kg and less than 90 kg
  • Willing and able to give informed consent
  • Additional inclusion criteria apply

For Japanese subjects only:

  • Subject must have been born in Japan, with 2 Japanese biological parents and 4 Japanese grandparents as confirmed by interview.
  • Subject has lived no longer than 10 years outside of Japan.
  • Subject had no significant change in lifestyle, including diet, since leaving Japan.

For Caucasian subjects only:

  • Subject has 2 Caucasian biological parents and 4 Caucasian grandparents as confirmed by interview.
  • Subject has lived no longer than 10 years outside of Europe and/or North America.

Exclusion criteria

For all subjects:

  • Subject is a female who is pregnant, lactating, breastfeeding, or planning to become pregnant during the study or within 7 days after the last dose of study drug.
  • Subject is a male who is planning to father a child during the study or within 7 days after the last dose of study drug.
  • Is positive for hepatitis A, B or C, and/or HIV
  • Has clinically significant abnormalities in baseline laboratory evaluations
  • Subject has a clinically significant abnormal electrocardiogram (ECG)
  • Participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to screening or is currently participating in another trial of an investigational drug (or medical device) Additional exclusion criteria apply

Treatment and study plan

TD-1473 - Dose A

Drug

oral capsule/tablet, QD

TD-1473 - Dose B

Drug

oral capsule/tablet, QD

TD-1473 - Dose C

Drug

oral capsule/tablet, QD

Placebo

Drug

oral capsule/tablet, QD

Primary outcomes

  1. Area under the concentration-time curve (AUC0 t)

    Time frame: Day 1 & Day 14

  2. Area under the concentration-time curve (AUC0 24)

    Time frame: Day 1 & Day 14

  3. Area under the concentration-time curve (AUCtau)

    Time frame: Day 1 & Day 14

  4. Maximum observed concentration (Cmax)

    Time frame: Day 1 & Day 14

  5. Maximum observed concentration at steady state (Cmax_ss)

    Time frame: Day 1 & Day 14

Sponsors and collaborators

Lead sponsor

Theravance Biopharma

Industry

Registry information

Official study title

A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Adult Japanese Subjects

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 23, 2018
Registry last updated
Jan 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.